FAKTOR NEKROZE TUMORA-α I MONOCITNI HEMOATRAKTANTNI PROTEIN-1 KAO BIOMARKERI U HRONIČNOJ MIJELOIDNOJ LEUKEMIJI
Sažetak
Hronične mijeloproliferativne neoplazme (engl. chronic myeloproliferative neoplasms – CMPNs) predstavljaju specifične klonske poremećaje hematopoetskih matičnih ćelija koji kontinuirano i bez prekida aktiviraju fiziološke puteve prenosa signala neophodne za normalnu i adekvatnu hematopoezu. Izražen proinflamatorni milje u hroničnoj mijeloidnoj leukemiji (engl. chronic myeloid leukemia – CML) predvode mnogi interleukini. Cilj ovog rada bio je da se procene razlike između nivoa faktora nekroze tumora-α (engl. tumor necrosis factor – TNF-α) i monocitnog hemoatraktantnog proteina-1 (engl. monocyte chemoattractant protein – MCP-1) u plazmi pacijenata u hroničnoj fazi hronične mijeloidne leukemije i zdravih osoba kao kontrolne grupe. Studija je obuhvatila pedeset pacijenata sa dijagnozom CML-a u hroničnoj fazi i na standardnoj terapiji inhibitorima tirozin kinaze (engl. tyrosine kinase inhibitors – TKIs) i dvadeset zdravih osoba u kontrolnoj grupi. Koncentracije TNF-α i MCP-1 u krvi merene su metodom ELISA (engl. enzyme-linked immunosorbent assay). Nivoi MCP-1 bili su viši kod pacijenata nego kod zdravih osoba (334,37 naspram 172,18 pg/ml; p = 0,006). S druge strane, nije utvrđena razlika kada je ispitivan TNF α. Velik je značaj MCP-1 i interleukina-6 (IL-6) kao novih, jakih i prediktivnih biomarkera u plazmi za remisiju CML-a bez lečenja. Dodatna i buduća istraživanja u ovoj oblasti biće posebno važna za razumevanje patofiziologije i lečenja mijeloproliferativnih bolesti.
Reference
Anand M, Chodda SK, Parikh PM, Nadkarni JS. Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis. Hematol Oncol 1998;16(4):143–54. [CrossRef] [PubMed]
Branford S. Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? Haematologica 2020;105(12):2730–7. [CrossRef] [PubMed]
Camacho V, Kuznetsova V, Welner RS. Inflammatory cytokines shape an altered immune response during myeloid malignancies. Front Immunol 2021;12:772408. [CrossRef] [PubMed]
Cashman JD, Eaves CJ, Sarris AH, Eaves AC (1998) MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood 1998;92(7):2338-44. [CrossRef] [PubMed]
Copland M. Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity. Br J Haematol 2022;199(5):665–78. [CrossRef] [PubMed]
Fisher DAC, Fowles JS, Zhou A, Oh ST. Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front Immunol 2021;12 683401. [CrossRef] [PubMed]
Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, et al. Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood 2013;122(19):3335–9. [CrossRef] [PubMed]
Hoermann G, Greiner G, Valent P. Cytokine regulation of microenvironmental cells in myeloproliferative neoplasms. Mediators Inflamm. 2015;2015:869242. [CrossRef] [PubMed]
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022;36(7):1703–19. [CrossRef] [PubMed]
Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK–STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 2015;5(3):316–31. [CrossRef] [PubMed]
Masselli E, Pozzi G, Gobbi G, Merighi S, Gessi S, Vitale M, et al. Cytokine profiling in myeloproliferative neoplasms: Overview on phenotype correlation, outcome prediction, and role of genetic variants. Cells 2020;9(9):2136. [CrossRef] [PubMed]
Mulholland BS, Forwood MR, Morrison NA. Monocyte chemoattractant protein-1 (MCP-1/CCL2) drives activation of bone remodelling and skeletal metastasis. Curr Osteoporos Rep 2019;17(6):538–47. [CrossRef] [PubMed]
Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, et al. TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia 2016;30(6):1263–72. [CrossRef] [PubMed]
Nishida A, Andoh A. The role of inflammation in cancer: Mechanisms of tumor initiation, progression, and metastasis. Cells 2025;14(7):488. [CrossRef] [PubMed]
Pavlovsky C, Cordoba BV, Sanchez MB, Moiraghi B, Varela A, Custidiano R, et al. Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal. J Hematol Oncol 2023;16(1):43. [CrossRef] [PubMed]
Wang Y, Zuo X. Cytokines frequently implicated in myeloproliferative neoplasms. Cytokine X 2019;1(1):100005. [CrossRef] [PubMed]
Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, et al. The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A 2005;102(38):13622–7. [CrossRef] [PubMed]
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer 2009;9(11):798–809. [CrossRef] [PubMed]
